All In Biotech

Drug Trial Radar · NCT04097769

The Safety, Tolerability, and Initial Efficacy of HX009 in Patients With Advanced Malignancies

A Phase I, First-in-Human Study Evaluating the Safety, Tolerability, and Initial Efficacy of HX009 in Patients With Advanced Malignancies

Last checked: Nov 19, 2026Latest source record: Dec 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

21

Actual

Start

Jun 12, 2019

Primary completion

Mar 18, 2021

Study completion Sep 29, 2022

Sponsor

Lead sponsor
Waterstone Hanxbio Pty LtdIndustry
Sponsor type
Industry
First posted
Sep 20, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human, multicenter, open-label, multiple-dose Phase I study to investigate the safety, tolerability, and initial efficacy of HX009 in subjects with advanced malignant tumors. The study will consist of a dose-escalation and dose-finding component to establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) and to evaluate the preliminary antitumor activity of HX009.

Conditions

  • Advanced Solid Tumor

Interventions

  • HX009Drug

    During study treatment, subjects will receive HX009 treatment via IV infusion once every 2 weeks at doses of 0.1, 0.3, 1, 2, 3, 5, and 7.5 mg/kg.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Experiencing Adverse Events (AEs)Time frame: All AEs up to 90 days after the last dose of study drug
  2. Number of Participants With Dose-Limiting Toxicities (DLT) of HX009Time frame: At the end of Cycle2(each cycle is 14 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • St George Private Hospital

    Kogarah, New South Wales, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.